INTRODUCTIONSelective radioiodine (RAI) therapy contributes to reducing the risk of recurrence and mortality in differentiated thyroid cancer (DTC) patients after thyroidectomy. So far, the optimal time to initiate RAI therapy after surgery remains unclear and no definite recommendations could be found in current relative guidelines. The initiating time of RAI varies worldwide and may be affected by personal, social environmental and disease‐related factors. Whether the initiating time will affect the clinical outcome of RAI treatment remains uncertain. Few clinical studies have focused on this issue with controversial conclusions. Higashi et al reported that delayed RAI therapy (>180 days after total thyroidectomy) may result in poor survival for DTC compared with early RAI therapy. Other authors claimed that the timing of RAI therapy would no impact the overall survival (OS) and disease‐free survival (DFS). It is noteworthy that in these studies, clinical outcome was evaluated in terms of OS and DFS. However, OS is not sufficient or appropriate to evaluate the clinical outcome for all patients with DTC, especially for those low‐ to intermediate‐risk patients, who had an excellent 5‐year OS more than 95%. Recently, a new therapy response system was proposed by the American Thyroid Association guideline (version 2015) (Table ).
Clinical Endocrinology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera